# Clinical Trial of Efficacy and Safety of the Combination of Reduced Duration Prophylaxis Followed by Immuno-guided Prophylaxis in Lung Transplant Recipients.

> **NCT03699254** · PHASE3 · COMPLETED · sponsor: **Maimónides Biomedical Research Institute of Córdoba** · enrollment: 150 (actual)

## Conditions studied

- Transplantation Infection
- Cytomegalovirus Infections

## Interventions

- **DRUG:** Valganciclovir
- **DRUG:** Ganciclovir

## Key facts

- **NCT ID:** NCT03699254
- **Lead sponsor:** Maimónides Biomedical Research Institute of Córdoba
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-05
- **Primary completion:** 2023-05-29
- **Final completion:** 2023-05-29
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2023-09-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03699254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03699254, "Clinical Trial of Efficacy and Safety of the Combination of Reduced Duration Prophylaxis Followed by Immuno-guided Prophylaxis in Lung Transplant Recipients.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03699254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*